SHANGYA Business Summary

Shangya Technology Co., Ltd. (6130.TWO) is a Taiwan-based enterprise that operates a diversified business model spanning healthcare distribution, semiconductor design, and renewable energy. The company generates revenue primarily through the wholesale of Chinese and Western pharmaceuticals, medical equipment, and beauty products, supplemented by the research, development, and sale of wireless communication and satellite positioning integrated circuits (ICs). Its operational segments are divided into health services—including clinic consultancy and beauty salon management—and a technology division focused on portable product ICs and solar power generation. Within the competitive landscape of the Taiwan OTC market, Shangya contends with direct peers such as Hi-Clearance (1788), Ma Kuang Healthcare (4139), Excelsior Biopharma (6496), and Sofiva Genomics (6615), positioning itself as a micro-cap hybrid player currently undergoing a strategic pivot following its 2023 rebranding from Singbao International. Originally founded in 1994, the company is currently led by Chairman Qian Kui Huang, who oversees a leadership team in significant transition as of March 2026. Following the dismissal of CEO Cai Yutan on March 13, 2026, the board appointed Cai Zhonghe as General Manager and Deputy Spokesperson on March 17, 2026, while Chen Fenxian, Assistant to the Chairman, assumed the role of Spokesperson. The executive suite has seen further vacancies following the resignation of CFO and Corporate Governance Officer Tseng Ying-Kuei on March 16, 2026, alongside a mass resignation of independent directors including Ke Cui-Ting and Wu Huang-Qing. The company’s ownership structure is anchored by major shareholder Xingbao Electronic Technology Co., Ltd., which maintains a significant stake as the firm seeks to stabilize its governance and return to profitability after recent fiscal losses.